Primary G-CSF prophylaxis for adjuvant TC or FEC-D chemotherapy outside of clinical trial settings: a systematic review and meta-analysis.

Background: Variable febrile neutropenia (FN) rates reported with adjuvant TC (taxotere®, cyclophosphamide) and FEC-D (5-flurouracil, epirubicin, cyclophosphamide, docetaxel) outside of clinical trials have precluded definitive recommendations for primary G-CSF (granulocyte colony-stimulating factor...

Descripción completa

Detalles Bibliográficos
Publicado en:Supportive Care in Cancer Vol. 20; no. 10; pp. 2523 - 2531
Autores principales: Younis T, Rayson D, Thompson K, Younis, Tallal, Rayson, Daniel, Thompson, Kara
Formato: meta analysis research systematic review Journal Article
Publicado: Springer Nature Oct2012
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104364658&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 104364658
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        09414355
        O1J
      jtl: Supportive Care in Cancer
      issn: 09414355
      maglogo: N
    pubinfo:
      dt: Oct2012
      vid: 20
      iid: 10
      pid: 237
      pub: Springer Nature
      place: New York, New York
    artinfo:
      ui:
        104364658
        NLM22252548
        2011669319
        10.1007/s00520-011-1375-6
        NLM22252548
        104364658
      ppf: 2523
      ppct: 8
      formats:
        fmt:
          @attributes:
            type: P
      tig:
        atl: Primary G-CSF prophylaxis for adjuvant TC or FEC-D chemotherapy outside of clinical trial settings: a systematic review and meta-analysis.
      aug:
        au:
          Younis T
          Rayson D
          Thompson K
          Younis, Tallal
          Rayson, Daniel
          Thompson, Kara
        affil: Atlantic Clinical Cancer Research Unit, Dalhousie University, Halifax, Nova Scotia, Canada
      sug:
        subj:
          Antineoplastic Agents, Combined Adverse Effects
          Fever Prevention and Control
          Granulocyte Colony-Stimulating Factor Therapeutic Use
          Neutropenia Prevention and Control
          Adult
          Aged
          Antineoplastic Agents, Combined Administration and Dosage
          Cyclophosphamide Administration and Dosage
          Doxorubicin Administration and Dosage
          Fever Chemically Induced
          Fluorouracil Administration and Dosage
          Human
          Hydrocarbons Administration and Dosage
          Medline
          Meta Analysis
          Middle Age
          Neutropenia Chemically Induced
          Systematic Review
          Adult: 19-44 years
          Aged: 65+ years
          Middle Aged: 45-64 years
      ab: Background: Variable febrile neutropenia (FN) rates reported with adjuvant TC (taxotere®, cyclophosphamide) and FEC-D (5-flurouracil, epirubicin, cyclophosphamide, docetaxel) outside of clinical trials have precluded definitive recommendations for primary G-CSF (granulocyte colony-stimulating factor) prophylaxis in most jurisdictions. A systematic review and meta-analysis was conducted to assess: (a) FN rates associated with TC and FEC-D without primary G-CSF prophylaxis outside of clinical trial settings, and (b) the potential impact of G-CSF prophylaxis on FN prevention.Methods: A MEDLINE search was conducted and major conference abstracts were reviewed up to June 15th 2011 to identify all relevant English-language studies. Random- and fixed-effects meta-analysis models were performed.Results: Nine hundred two patients treated with TC and 1342 with FEC-D from 13 to 9 studies, respectively, were included. The pooled random-effects meta-analysis estimates of FN rates for TC and FEC-D without G-CSF were 29% (95% CI 24-35%) and 31% (95% CI 27-35%), with a 76% (RR = 0.24, 95% CI 0.14-0.41) and 63% (RR = 0.37, 95% CI 0.11-1.24) relative risk reduction with G-CSF, respectively.Conclusion: In routine clinical practice, TC and FEC-D without G-CSF are associated with FN rates exceeding the 20% threshold for which primary G-CSF prophylaxis is commonly recommended, and are considerably higher than those reported in pivotal clinical trials.
      pubtype: Academic Journal
      doctype:
        meta analysis
        research
        systematic review
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N